Our FDA: Drug & Device Team examines the FDA’s new draft guidance that allows biosimilar developers to rely more on analytical and pharmacokinetic data, reducing the need for costly and time-consuming comparative efficacy studies.
| less than a minute read
Comparative Efficacy Studies No Longer a Default for Biosimilars | Alston & Bird
/Passle/684ab3969b37aca8151f950e/SearchServiceImages/2025-12-24-22-49-37-295-694c6e01b6062d4a21e6f822.jpg)
/Passle/684ab3969b37aca8151f950e/SearchServiceImages/2025-12-23-20-26-04-134-694afadcfb64d8ffeb989b31.jpg)
/Passle/684ab3969b37aca8151f950e/SearchServiceImages/2025-12-23-20-19-43-373-694af95f05335a16ce0be1e8.jpg)